Benzinga - by Vandana Singh, Benzinga Editor.
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard-of-care antihypertensives.
The company announced the topline results from the KARDIA-2 study in March 2024.
When added to the standard of care, indapamide and, amlodipine, zilebesiran respectively achieved reductions of 12.1 mmHg (p
However, when added to olmesartan, the experimental drug delivered a 4 mmHg reduction, missing statistical significance (p=0.036).
Similarly, when added to the standard of care, indapamide and, amlodipine, zilebesiran, respectively, achieved reductions of 11.0 mmHg (p
However, statistical significance was missed in the olmesartan arm, with a reduction of 1.6 mmHg (p=0.26).
Alnylam Pharmaceuticals and its partner Roche Holdings AG (OTC:RHHBY) have initiated a Phase 2 KARDIA-3 study of zilebesiran on top of 2-4 anti-hypertensive medicines and are planning a Phase 3 CVOT, JMP Securities writes.
The analyst recommends owning Alnylam shares ahead of HELIOS-B data on AMVUTTRA in ATTR-CM in late June or early July. If positive, Alnylam will file the FDA marketing application by the end of 2024 and use a priority review voucher for approval in 2H 2025.
JMP reiterates the Overweight rating, with a price target of $217.
William Blair writes that although there could be noise in interpreting the Olmesartan cohort of KARDIA-2, the zilebesiran data is strong here and has invoked genuine interest.
With approximately 219 million patients in seven key markets, the primary hypertension market is substantial, making the zilebesiran market significant for Alnylam financially.
While investor attention is on the HELIOS-B cardiovascular outcomes trial for vutrisiran in TTR-cardiomyopathy, expected in June or early July,
Alnylam is actively progressing its RNA-targeted therapeutics pipeline. Therefore, William Blair maintains the Outperform rating on Alnylam.
Price Action: ALNY shares are up 2.46% at $157.34 on the last check Monday.
Latest Ratings for ALNY
| Mar 2022 | Citigroup | Initiates Coverage On | Buy | |
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | SVB Leerink | Maintains | Market Perform |
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.